37 related articles for article (PubMed ID: 38537440)
1. Tanshinone IIA acts as a regulator of lipogenesis to overcome osimertinib acquired resistance in lung cancer.
Cao L; Qin Z; Yu T; Bai X; Jiang S; Wang D; Ning F; Huang M; Jin J
Biochem Pharmacol; 2024 Jun; 224():116207. PubMed ID: 38621425
[TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA inhibits proliferation and migration by downregulation of the PI3K/Akt pathway in small cell lung cancer cells.
Jiang Y; Bi Y; Zhou L; Zheng S; Jian T; Chen J
BMC Complement Med Ther; 2024 Jan; 24(1):68. PubMed ID: 38297301
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapy.
Liang Y; Luo H; Li X; Liu S; Habib A; Liu B; Huang J; Wang J; Yi H; Hu B; Zheng L; Xie J; Zhu N
Front Immunol; 2024; 15():1367040. PubMed ID: 38745661
[TBL] [Abstract][Full Text] [Related]
5. Solamargine improves the therapeutic efficacy of anti-PD-L1 in lung adenocarcinoma by inhibiting STAT1 activation.
Liu Q; Xu M; Qiu M; Yu J; Wang Q; Zhou Y; Lin Q; Cai X; Yang L; Zhao H; Zhao C; Xie X
Phytomedicine; 2024 Jun; 128():155538. PubMed ID: 38552432
[TBL] [Abstract][Full Text] [Related]
6. Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression.
Yin C; Pa Y; Li G; Chen Q; Wang X; He X; Zhou H
Immunopharmacol Immunotoxicol; 2024 Jun; 46(3):417-423. PubMed ID: 38678437
[TBL] [Abstract][Full Text] [Related]
7. Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc.
Wang J; Yang Y; Shao F; Meng Y; Guo D; He J; Lu Z
Nat Metab; 2024 May; 6(5):914-932. PubMed ID: 38702440
[TBL] [Abstract][Full Text] [Related]
8. Tanshinone IIA alleviates pulmonary fibrosis by modulating glutamine metabolic reprogramming based on [U-
Shan B; Guo C; Zhou H; Chen J
J Adv Res; 2024 May; ():. PubMed ID: 38697470
[TBL] [Abstract][Full Text] [Related]
9. Expression of RIPK1 and FADD are associated with chemosensitivity and survival in head and heck squamous cell carcinoma via tanshinone IIA-mediated modulation of the RIPK1-FADD-Caspase 8 complex.
Shen B; Han W; Tan X; Gu KJ; Naseem DF; Zheng G; Li G; Lou J; Chen C
Mol Carcinog; 2024 May; ():. PubMed ID: 38695620
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and mechanism of the Chinese medicine Weiren Xiaoyou formula in improving palmoplantar warts.
Liu X; Xi R; Cheng L; Wang Y; Nie Y; Yan G; Guo D; Guo W; Du T; Lu H; Wang P; Zhu J; Li F
Heliyon; 2024 May; 10(10):e31376. PubMed ID: 38818172
[TBL] [Abstract][Full Text] [Related]
11. Combination of percutaneous thermal ablation and adoptive Th9 cell transfer therapy against non-small cell lung cancer.
Pan H; Tian Y; Pei S; Yang W; Zhang Y; Gu Z; Zhu H; Zou N; Zhang J; Jiang L; Hu Y; Shen S; Wang K; Jin H; Li Z; Zhang Y; Xiao Y; Luo Q; Wang H; Huang J
Exp Hematol Oncol; 2024 May; 13(1):52. PubMed ID: 38760861
[TBL] [Abstract][Full Text] [Related]
12. Global implementation of individualized lung cancer care requires wide adoption of molecular tumor profiling.
Deboever N; Antonoff MB
J Thorac Dis; 2024 Apr; 16(4):2698-2701. PubMed ID: 38738258
[No Abstract] [Full Text] [Related]
13. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
15. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
[TBL] [Abstract][Full Text] [Related]
16. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication.
Tancoš V; Blichárová A; Plank L
Klin Onkol; 2022; 35(5):372-376. PubMed ID: 36443097
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
